ARS Pharmaceuticals (SPRY) Short term Debt (2020 - 2021)
ARS Pharmaceuticals (SPRY) posted Short term Debt of $495000.0 for Q1 2021, down 41.35% sequentially from $844000.0 in Q4 2020.
Powered by 
Analysis
ARS Pharmaceuticals (SPRY) Short term Debt (2020 - 2021) Analysis & Trends
ARS Pharmaceuticals has reported Short term Debt for 2 years, with the latest figure at $495000.0 in Q1 2021.
- Quarterly Short term Debt changed N/A year-over-year to $495000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $495000.0 (changed N/A YoY) and the FY2020 annual result came in at $844000.0, changed N/A from the prior year.
- Short term Debt declined to $495000.0 in Q1 2021 per SPRY's latest filing, from $844000.0 in the prior quarter.
- Over five years, Short term Debt peaked at $844000.0 in Q4 2020 and troughed at $495000.0 in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.12 Mn | 417.27 Mn | 20.81 Mn |